A detailed history of International Biotechnology Trust PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, International Biotechnology Trust PLC holds 12,700 shares of BGNE stock, worth $2.26 Million. This represents 0.78% of its overall portfolio holdings.

Number of Shares
12,700
Previous 8,700 45.98%
Holding current value
$2.26 Million
Previous $1.55 Million 47.26%
% of portfolio
0.78%
Previous 0.48%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$179.87 - $225.13 $719,480 - $900,520
4,000 Added 45.98%
12,700 $2.28 Million
Q2 2023

Aug 08, 2023

SELL
$178.3 - $266.78 $2.5 Million - $3.73 Million
-14,000 Reduced 61.67%
8,700 $1.55 Million
Q1 2023

May 18, 2023

BUY
$215.53 - $274.5 $1.51 Million - $1.92 Million
7,000 Added 44.59%
22,700 $4.89 Million
Q3 2022

Nov 08, 2022

BUY
$131.8 - $202.24 $1.73 Million - $2.66 Million
13,158 Added 517.62%
15,700 $2.12 Million
Q2 2022

Aug 16, 2022

SELL
$121.11 - $216.05 $1.59 Million - $2.84 Million
-13,158 Reduced 83.81%
2,542 $15.7 Million
Q1 2022

May 20, 2022

SELL
$146.52 - $269.56 $630,036 - $1.16 Million
-4,300 Reduced 21.5%
15,700 $2.96 Million
Q4 2021

Feb 15, 2022

BUY
$248.56 - $389.34 $4.97 Million - $7.79 Million
20,000 New
20,000 $5.4 Million
Q1 2020

May 18, 2020

SELL
$121.84 - $173.19 $1.71 Million - $2.42 Million
-14,000 Closed
0 $0
Q4 2019

May 18, 2020

SELL
$115.78 - $208.34 $27.7 Million - $49.9 Million
-239,522 Reduced 94.48%
14,000 $2.32 Million
Q3 2018

Nov 13, 2018

BUY
$152.62 - $189.66 $38.7 Million - $48.1 Million
253,522 New
253,522 $17.4 Million
Q2 2018

Aug 13, 2018

SELL
$152.5 - $216.77 $1.45 Million - $2.06 Million
-9,500 Closed
0 $0
Q4 2017

Mar 02, 2018

BUY
$79.6 - $114.73 $756,200 - $1.09 Million
9,500 New
9,500 $928,000
Q2 2017

Mar 02, 2018

SELL
N/A
-66,041 Closed
0 $0
Q1 2017

Mar 02, 2018

BUY
N/A
66,041
66,041 $2.42 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track International Biotechnology Trust PLC Portfolio

Follow International Biotechnology Trust PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of International Biotechnology Trust PLC, based on Form 13F filings with the SEC.

News

Stay updated on International Biotechnology Trust PLC with notifications on news.